Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry

Shen,Hongqiang; Tang,Yongmin; Dong,Ao; Li,Huamei; Shen,Diying; Yang,Shilong; Tang,Hongfeng; Gu,Weizhong; Shu,Qiang

doi:10.3892/ol.2014.1854

Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry

Authors:
- Hongqiang Shen
- Yongmin Tang
- Ao Dong
- Huamei Li
- Diying Shen
- Shilong Yang
- Hongfeng Tang
- Weizhong Gu
- Qiang Shu
View Affiliations

Affiliations: Division of Hematology and Key Laboratory of Reproductive Genetics, Zhejiang University, Ministry of Education, Hangzhou, Zhejiang 310003, P.R. China, Division of Pathology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Division of Surgery, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China
Published online on: February 4, 2014 https://doi.org/10.3892/ol.2014.1854
Pages: 970-976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The detection of contaminating RMS cells in the bone marrow (BM) is important in clinical staging and risk assessment. The cytological examination of the BM remains the gold standard for the diagnosis of RMS, but has a limited sensitivity. In the present study, 32 BM and two cerebrospinal fluid (CSF) samples from 11 patients with suspected metastasis were analyzed by flow cytometry (FCM) with ganglioside D2 (GD2) conjugated with ﬂuorescein isothiocyanate, cluster of differentiation (CD)90‑phycoerythrin, CD45‑peridinin chlorophyll protein and CD56‑allophycocyanin monoclonal antibody cocktail in parallel to morphological examination at diagnosis or during treatment. Five samples (14.7%) were positive for RMS onup morphological examination. By FCM, 16 samples (47.1%) were positive for RMS. A significant difference was identified between the two methods. The four‑color FCM assay successfully detected RMS cells in BM samples to a level of 0.01% (1 per 104 cells). RMS cells demonstrated a phenotype with CD56+/CD90+/CD45-/GD2- expression, which is different from the CD56+/CD90+/CD45-/GD2+ expression phenotype in neuroblastoma cells. The follow‑up of four patients by FCM demonstrated that two patients became minimal residual disease‑negative following two and four cycles of chemotherapy, respectively, and survived. The other two cases remained FCM‑positive despite receiving four courses of chemotherapy and consequently succumbed to progressive disease. In addition, FCM analysis of the CSF samples from one patient confirmed a diagnosis of CSF metastasis with RMS. In conclusion, FCM may have a role not only in staging and monitoring the effects of therapy, but also in providing diagnostic confirmation of CSF metastasis with RMS.

View Figures

View References

1	Dasgupta R and Rodeberg DA: Update on rhabdomyosarcoma. Semin Pediatr Surg. 21:68–78. 2012. View Article : Google Scholar : PubMed/NCBI
2	McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C and Bergeron C: Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 46:1588–1595. 2010. View Article : Google Scholar
3	Ohta H, Hashii Y, Yoshida H, et al: Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 33:e35–e38. 2011. View Article : Google Scholar : PubMed/NCBI
4	Palma J, Sasso DF, Dufort G, et al: Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant. 47:522–527. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sartori F, Alaggio R, Zanazzo G, et al: Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer. 106:1766–1775. 2006. View Article : Google Scholar
6	Stegmaier S, Poremba C, Schaefer KL, et al: Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer. 57:406–414. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang XL, Zhang SC, Zhang SW and Wang H: Detection of PAX3/PAX7-FKHR fusion transcripts in rhabdomyosarcoma and other small round cell tumors by 1-step reverse transcriptase polymerase chain reaction: a novel tool for diagnosis and differentiation. Ann Diagn Pathol. 16:107–111. 2012. View Article : Google Scholar
8	Gautam U, Srinivasan R, Rajwanshi A, Bansal D and Marwaha RK: Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens. Cancer. 114:494–503. 2008. View Article : Google Scholar
9	Bozzi F, Collini P, Aiello A, et al: Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma. Anticancer Res. 28:1565–1569. 2008.PubMed/NCBI
10	Ferreira-Facio CS, Milito C, Botafogo V, et al: Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer. PLoS One. 8:e555342013. View Article : Google Scholar
11	Sethuraman C, Simmerson M, Vora AJ and Cohen MC: Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use? J Pediatr Hematol Oncol. 32:298–303. 2010. View Article : Google Scholar
12	Swerts K, De Moerloose B, Dhooge C, et al: Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry. Cytometry B Clin Cytom. 61:9–19. 2004. View Article : Google Scholar : PubMed/NCBI
13	Matthay KK, George RE and Yu AL: Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 18:2740–2753. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shen H, Tang Y, Xu X and Tang H: Detection of the GD2+/1CD56+/CD45− immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma. Pediatr Hematol Oncol. 30:30–32. 2013.
15	Stall JN and Bailey NG: Metastatic alveolar rhabdomyosarcoma to the bone marrow mimicking acute leukemia. Blood. 120:36322012. View Article : Google Scholar : PubMed/NCBI
16	Jelić-Puskarić B, Rajković-Molek K, Raić L, Batinić D, Konja J and Kardum-Skelin I: Rhabdomyosarcoma with bone marrow infiltration mimicking hematologic neoplasia. Coll Antropol. 34:635–639. 2010.PubMed/NCBI
17	Cai JY, Tang YJ, Jiang LM, Pan C, Chen J and Tang JY: Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer. 49:952–957. 2007.PubMed/NCBI
18	Esser R, Glienke W, Bochennek K, et al: Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR. Klin Padiatr. 223:326–331. 2011. View Article : Google Scholar
19	Cai JY, Pan C, Tang YJ, et al: Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration. Am J Clin Oncol. 35:275–278. 2012. View Article : Google Scholar : PubMed/NCBI
20	Raney B, Huh W, Hawkins D, et al: Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984–1997: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 60:371–376. 2013.PubMed/NCBI
21	Ahluwalia MS, Wallace PK and Peereboom DM: Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: ready for prime time? Cancer. 118:1747–1753. 2012. View Article : Google Scholar : PubMed/NCBI